Pierre Fabre

Vinorelbine is a vinca chemotherapy for lung and breast cancer, available orally, and is now part of maintenance therapy that improved survival in childhood rhabdomyosarcoma.

Vinflunine (Javlor) is a chemotherapy infusion used in Europe as a second treatment for advanced bladder cancer after platinum chemotherapy has stopped working.

Encorafenib is a BRAF inhibitor that, with cetuximab and chemotherapy, became first-line standard for BRAF-mutant colorectal cancer in 2026.

Binimetinib is the MEK inhibitor partnered with encorafenib; blocking the next step in the same relay stops the tumour rerouting around the BRAF block.

Busulfan is one of the oldest cancer drugs. As a tablet it controlled chronic myeloid leukaemia before imatinib; as an infusion it is used to clear the bone marrow before a stem cell transplant.

Hemangeol is a liquid form of the blood-pressure drug propranolol approved to shrink infantile haemangiomas, the common benign blood-vessel tumours of babies, replacing steroids and surgery for most children who need treatment.

Tabelecleucel is a bank of donor T cells trained against Epstein-Barr virus, approved in Europe in 2022 as the first off-the-shelf T-cell therapy, for EBV-driven lymphoma after transplant when rituximab has failed.